PALO ALTO, Calif., July 7, 2020 /PRNewswire/ -- Kodiak Sciences Inc.
(Nasdaq: KOD), a clinical stage biopharmaceutical company
specializing in novel therapeutics to treat chronic,
high-prevalence retinal diseases, today announced that new data
from the ongoing Phase 1b study of
KSI-301, its novel anti-VEGF antibody biopolymer conjugate, will be
presented at the upcoming American Society of Retina Specialists
(ASRS) 2020 Virtual Annual Meeting.
The presentation is expected to be made available online to ASRS
members and meeting attendees via the ASRS Mobile Meeting App on
the afternoon of July 10, 2020.
A livestreamed discussion/Q&A panel will be held on
Sunday, July 26, 2020, for ASRS
Virtual Annual Meeting attendees.
On July 10, 2020, at the time the
presentation is released on the ASRS Mobile Meeting App, Kodiak
plans to post the slide presentation on the Kodiak Investor
Relations website at http://ir.kodiak.com/.
On July 27, 2020, following the
livestreamed discussion, Kodiak plans to hold an R&D webinar to
discuss the new Phase 1b data and its
applicability to Kodiak's ongoing and planned registrational
studies for KSI-301.
"We now have over 150 patient-years of experience with KSI-301
across our clinical program, and the Phase 1b data to be presented at ASRS include results
from nearly 550 injections in 121 patients with wet AMD, diabetic
macular edema, or retinal vein occlusion, many of whom have been
followed for a year or longer," said Victor
Perlroth, M.D., Chief Executive Officer of Kodiak Sciences.
"We have previously announced excellent safety, strong efficacy and
remarkable durability with KSI-301 in these treatment-naïve patient
cohorts. Over the last six months, the data have continued to
mature nicely, and we continue to be highly encouraged by KSI-301's
Generation 2.0 anti-VEGF therapeutic profile and the probability of
success in our ongoing and forthcoming pivotal studies, which cover
all the major indications for anti-VEGF therapy. We look forward to
the ASRS presentation and to engaging with the community after the
data are released."
Details of the presentation are as follows:
Oral Presentation: One-Year and Beyond: Results of
Phase 1b Study of KSI-301, an
Anti-VEGF Antibody Biopolymer Conjugate with Extended Durability,
in wAMD, DME, and RVO
Presenter: Mark Barakat, M.D. -- Retinal Consultants of
Arizona, Retinal Research
Institute, Phoenix, AZ
Expected Presentation Availability via ASRS Mobile Meeting
App: Friday, July 10, 2020 – 4:00
PM Eastern Time.
Virtual Meeting Session: Wet AMD Symposium 3
Virtual Meeting Livestreamed Panel Discussion Date and
Time: Sunday, July 26, 2020 – 11:10
AM Eastern Time (open to registered meeting attendees
only)
Kodiak plans to issue a press release remarking on the data and
to post the slide presentation on the Kodiak Investor Relations
website at http://ir.kodiak.com/ at the time the ASRS presentation
is released on the ASRS Mobile Meeting App.
Registration details for Kodiak's R&D Webinar planned for
July 27, 2020 will be provided closer
to the event.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a clinical stage biopharmaceutical
company developing novel therapeutics to treat chronic,
high-prevalence retinal diseases. Founded in 2009, we are focused
on bringing new science to the design and manufacture of next
generation retinal medicines to prevent and treat the leading
causes of blindness globally. Our ABC Platform™ uses molecular
engineering to merge the fields of antibody-based and
chemistry-based therapies and is at the core of Kodiak's discovery
engine. Kodiak's lead product candidate, KSI-301, is a novel
anti-VEGF antibody biopolymer conjugate being developed for the
treatment of retinal vascular diseases including age-related
macular degeneration, a leading cause of blindness in elderly
patients, and diabetic retinopathy, a leading cause of blindness in
working-age patients. Kodiak has leveraged its ABC Platform to
build a pipeline of product candidates in various stages of
development including KSI-501, our bispecific anti-IL-6/VEGF
biopolymer conjugate for the treatment of neovascular retinal
diseases with an inflammatory component, and we are expanding our
early research pipeline to include ABC Platform based triplet
inhibitors for multifactorial retinal diseases such as dry AMD and
glaucoma. Kodiak is based in Palo Alto, CA. For more
information, please visit www.kodiak.com.
Forward-Looking Statements
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding
future development plans and the potential licensure of KSI-301;
our platform technology and potential therapies; clinical and
regulatory objectives and the timing thereof, anticipated design of
planned clinical trials, expectations regarding the potential
efficacy and commercial potential of our product candidates; the
anticipated presentation of data; the results of our research and
development efforts and our ability to advance our product
candidates into later stages of development. Forward-looking
statements generally include statements that are predictive in
nature and depend upon or refer to future events or conditions, and
include words such as "may," "will," "should," "would," "expect,"
"plan," "believe," "intend," "pursue," and other similar
expressions among others. Any forward-looking statements are based
on management's current expectations of future events and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks
and uncertainties include, but are not limited to, the preliminary
safety, efficacy and durability data for our KSI-301 product
candidate may not continue or persist; cessation or delay of any of
the ongoing clinical studies and/or our development of KSI-301 may
occur; future potential regulatory milestones of KSI-301, including
those related to current and planned clinical studies may be
insufficient to support regulatory submissions or approval;
anticipated presentation of data at upcoming conferences may not
occur; our research and development efforts and our ability to
advance our product candidates into later stages of development may
fail; any one or more of our product candidates may not be
successfully developed, approved or commercialized; adverse
conditions in the general domestic and global economic markets; as
well as the other risks identified in our filings with the
Securities and Exchange Commission. For a discussion of other risks
and uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled "Risk Factors"
in our most recent Form 10-Q, as well as discussions of potential
risks, uncertainties, and other important factors in our subsequent
filings with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof and
Kodiak undertakes no obligation to update forward-looking
statements, and readers are cautioned not to place undue reliance
on such forward-looking statements.
Kodiak®, Kodiak Sciences®, ABC™, ABC
Platform™ and the Kodiak logo are registered trademarks or
trademarks of Kodiak Sciences Inc. in various global
jurisdictions.
View original
content:http://www.prnewswire.com/news-releases/kodiak-sciences-announces-upcoming-presentation-of-ksi-301-clinical-study-data-at-american-society-of-retina-specialists-asrs-2020-virtual-annual-meeting-and-rd-webinar-301088962.html
SOURCE Kodiak Sciences Inc.